<DOC>
	<DOCNO>NCT02498535</DOCNO>
	<brief_summary>Prospective , randomize , placebo control , phase II clinical study subject cross approve inhaled antibiotic inhale nitric oxide compare placebo control arm .</brief_summary>
	<brief_title>Efficacy Safety Inhaled Nitric Oxide ( NO ) Cystic Fibrosis ( CF ) Patients</brief_title>
	<detailed_description>This multi-center , randomize , placebo control , phase II clinical study compare investigational drug placebo control . Screening data review determine subject eligibility . All subject include screen failure subject record screen log respective site . Upon successful completion screening procedure , subject consider eligible enrollment . The subject enrol randomize close time proximity first treatment application possible order minimize possibility dropout enrol undergoing treatment . With 1:1 investigational treatment placebo control , subject randomize one two arm . Subjects investigational treatment arm administer dose NO ( 0.5 % NO 99.5 % nitrogen ) dilute room air inhalation four time daily ( 30-minute inhalation least 3 hour apart ) 7.5 day Days 1 , 2 , 3 , 4 , 5 , 8 , 9 , 10 ( three treatment Days 1 10 ) . Subjects placebo arm breathe 100 % nitrogen dilute room air proportion investigational arm . Subjects remain clinic 30 minute complete last treatment day . All subject ask return clinic additional evaluation Days 15 36 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>1 . Confirmed diagnosis Cystic Fibrosis base follow criterion : positive sweat chloride 60 mEq/liter ( pilocarpine iontophoresis ) ; and/or genotype two identifiable mutation consistent CF 2 . Presence Pseudomonas aeruginosa , Staphylococcus aureus Stenotrophomonas maltophilia screen sputum culture . 3 . Chronic microbial lung colonization ( ≥6 month ) presence Pseudomonas aeruginosa , Staphylococcus aureus Stenotrophomonas maltophilia least two ( 2 ) sputum culture past year ( screening culture count one two positive culture ) . 4 . Ongoing chronic inhale antibiotic therapy least 3 month prior ( screen baseline ) . • For subject cycle therapy , least 2 cycle drug need complete prior baseline . 5 . Willing inhaled antibiotic therapy Day 1 Day 15 6 . Male female subject ≥18 year 7 . FEV1 &lt; 85 % &gt; 35 % screen baseline 8 . SaO2 &gt; 90 % room air screen baseline 9 . Clinically stable significant change health status within 14 day prior Baseline 10 . Written Informed Consent HIPAA authorization 11 . Nonsmoker least 6 month prior screen agrees smoke study 12 . Chest xray within last six ( 6 ) month . If none , chest xray require randomization . 13 . Willing able comply treatment schedule procedure . 1 . Initiation new chronic therapy ( e.g. , ibuprofen , Pulmozyme® , hypertonic saline , azithromycin , TOBI® , Cayston® ) within 4 week prior screen . 2 . Use antibiotic [ oral , intravenous ( iv ) , and/or inhaled ] acute respiratory symptom within 2 week prior baseline . 3 . Significant hemoptysis within 30 day prior screen ( ≥5 mL blood one coughing episode &gt; 30 mL blood 24 hour period ) 4 . History colonization nontuberculosis mycobacterium sputum culture . The investigator guide follow suggest criterion subject consider free colonization : Two respiratory tract culture negative NTM last year , subsequent positive culture ; 2 respiratory culture must separate least 3 month ; one two culture obtain within last 6 month 5 . Cardiac ( left heart ) insufficiency ( define LVEF &lt; 35 % ) screen 6 . Use nitric oxide donor agent nitroglycerin drug know increase methemoglobin lidocaine , prilocaine , benzocaine dapsone screen 7 . Any following abnormal lab value Screening : Hemoglobin &lt; 10 g/dl Methemoglobn &gt; 3 % Platelet count &lt; 100,000/mm3 Prothrombin time international ratio ( INR ) &gt; 1.5 Abnormal liver function define two following : ALT &gt; 3 x ULN AST &gt; 3 x ULN ALP &gt; 3 x ULN GGT &gt; 3 x ULN Abnormal liver function define : ALT &gt; 5 x ULN AST &gt; 5 x ULN Abnormal renal function define : Calculated Creatinine Clearance &lt; 50 mL ( calculated Cockcroft/Gault ) 8 . For woman child bear potential : positive pregnancy test screen lactate unwilling practice medically acceptable form contraception screen Day 36 ( acceptable form contraception : abstinence , hormonal birth control , intrauterine device , barrier method plus spermicidal agent ) 9 . Use investigational drug within 30 day prior screen 10 . Intravenous oral steroid 14 day prior screen 11 . Current use inhale steroid &gt; 500 microgram twice daily Fluticasone equivalent 30 day prior screen 12 . Use supplemental oxygen ( daytime nocturnal ) 7 day prior screen 13 . Any condition Investigator believe would interfere intent study would make participation best interest subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>